Product Description
a Topical Formulation for the Treatment of Psoriasis Vulgaris (Sourced from: https://clinicaltrials.gov/ct2/history/NCT01743118?V_3=View)
Mechanisms of Action: Potassium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Circassia
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Psoriasis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01743118 |
SP001 | P1 |
Completed |
Psoriasis |
2013-07-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|